<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Hereditary hemorrhagic <z:hpo ids='HP_0001009'>telangiectasia</z:hpo> (HHT), also known as <z:e sem="disease" ids="C0039445" disease_type="Disease or Syndrome" abbrv="">Rendu-Osler-Weber syndrome</z:e>, is an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> disease that leads to multiregional <z:e sem="disease" ids="C0267370,C0085411" disease_type="Disease or Syndrome" abbrv="">angiodysplasia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The presence of <z:hpo ids='HP_0001009'>telangiectasias</z:hpo> in nasal mucosa leads to <z:hpo ids='HP_0004406'>recurrent epistaxis</z:hpo> that affects up to 96% of patients but with unpredictable severity </plain></SENT>
<SENT sid="2" pm="."><plain>Some authors have previously explained that endonasal <z:mp ids='MP_0000002'>morphology</z:mp> and distribution of <z:hpo ids='HP_0001009'>telangiectasias</z:hpo> can be variable too </plain></SENT>
<SENT sid="3" pm="."><plain>The purpose of this study was to evaluate any possible relationship between the severity of <z:hpo ids='HP_0000421'>epistaxis</z:hpo> and the different <z:mp ids='MP_0000002'>morphology</z:mp> and distribution of nasal <z:hpo ids='HP_0001009'>telangiectasias</z:hpo> in HHT patients </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: A review was performed of nasal endoscopy records of 76 consecutive HHT patients treated for <z:hpo ids='HP_0000421'>epistaxis</z:hpo> between 2003 and 2007 at our institution </plain></SENT>
<SENT sid="5" pm="."><plain>An evaluation was performed of severity of <z:hpo ids='HP_0000421'>epistaxis</z:hpo> in the same patient group using a questionnaire and considering frequency, intensity, duration of <z:hpo ids='HP_0000421'>nosebleeds</z:hpo>, and need for blood transfusions </plain></SENT>
<SENT sid="6" pm="."><plain>Comparison of data collected on <z:mp ids='MP_0000002'>morphology</z:mp> and distribution of nasal <z:hpo ids='HP_0001009'>telangiectasias</z:hpo> with data collected on severity of <z:hpo ids='HP_0000421'>epistaxis</z:hpo> was performed </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:mp ids='MP_0000002'>Morphology</z:mp> and distribution of nasal <z:hpo ids='HP_0001009'>telangiectasias</z:hpo> showed a statistically significant correlation with frequency and intensity of <z:hpo ids='HP_0000421'>epistaxis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Presence of <z:hpo ids='HP_0001009'>telangiectasias</z:hpo> endoscopically appearing as large and prominent correlates with higher frequency of <z:hpo ids='HP_0000421'>epistaxis</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>An increase in number of nasal subsites involved correlates with higher intensity of <z:hpo ids='HP_0000421'>nosebleeds</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Our data suggest that to reduce frequency and intensity of <z:hpo ids='HP_0000421'>epistaxis</z:hpo> in HHT patients, treatments should be directed also at lesions located in the posterior part of nasal fossae and especially on <z:hpo ids='HP_0001009'>telangiectasias</z:hpo> endoscopically appearing as large and prominent </plain></SENT>
</text></document>